Chapter 85: Will Qingshan Pharmaceutical agree to this price? (Ask for monthly ticket)
Speaking, Zhou Hai pressed the projector pen again, and another detailed data chart appeared on the screen.
“This data has not been released by Qingshan Pharmaceutical to the public yet. You can take a closer look.”
“There are a total of 98 subjects in the first batch of their clinical phase III. 49 patients in the control group and 49 patients in the experimental group were cured, and the overall actual cure rate was as high as 95.98%!
95.98%!
After the words fell, all the leadership experts present looked at the screen with disbelief in their eyes.
In fact, many people present noticed that when Qingshan Pharmaceutical said that more than 90% of the cure would be achieved in the third phase of clinical trials, they scoffed, and some even did not believe it!
But now, the effective cure rate of "Ecofovir" not only exceeds 90%, but also reaches an astonishing 95.98%!
This data can be used to promote the complete cure of hepatitis B!
At this moment, Zhou Hai coughed lightly and pressed down the projector pen again.
“The only two remaining people among the 49 people have not been cured because they are hepatitis B patients transmitted from mother to child.”
“Compared with hepatitis B patients who were infected the day after tomorrow, Hepatitis B patients who are transmitted from mother to child are more difficult to cure; we have also communicated with Qingshan Pharmaceutical about this matter ,
They said that they are trying to let the patient continue to take the medicine for two months, and there is a high probability that the patient can be cured! ”
“In other words, Qingshan Pharmaceutical’s ‘Icofenprovir’ 'Except for mother-to-child hepatitis B patients, the actual cure rate is 100%."
100%! ! !
Many people in the conference room took a breath. The cure rate of 95.9% was surprising enough, but they did not expect that the final result would be - 100%!
The crowd's expressions fell in Zhou Hai's eyes, and he was not surprised, because he had the same expression when he saw the clinical data two days ago.
He continued:
“Okay, now everyone is very clear about the current actual effect of this drug, so let’s officially get to the topic of today.”
"According to the terms of the 'Starlight Plan', this drug will be included in our medical insurance procurement catalog after it is launched."
"As we all know, there are a large number of hepatitis B patients in our country and its impact is far-reaching. After this drug is included in the medical insurance It is undoubtedly a huge expense for the medical insurance fund! ”
"Therefore, we must carry out price research and judgment on this drug as soon as possible and give the comrades of the Medical Insurance Bureau a psychological floor price so that they can have a certain understanding of the situation when negotiating with Tsingshan Pharmaceutical and have a certain degree of negotiation initiative. "
After the words fell, everyone nodded, and their expressions gradually became serious.
At this moment, a middle-aged man sitting in the front row of the conference table suddenly stood up. He first made an apologetic gesture to Zhou Hai, and then turned to look at the people around him. Bowing with both hands:
"Dear leaders, experts, and colleagues, I am Liu Weiguo from the Medical Insurance Bureau."
"Before the discussion, I hope everyone will do well and think more about the difficulties of our Medical Insurance Bureau. We must use this drug The expected price is set lower, otherwise you won’t be able to get so much money if you kill us!”
The bow made everyone laugh.
Of course everyone can hear Liu Weiguo’s somewhat joking tone. After all, today’s seminar is just an official internal meeting, and what is discussed is only the psychological price. The final price has to be negotiated with Qingshan Pharmaceutical. Sure.
However,
Everyone could also hear the helplessness and sadness in Liu Weiguo's words. Over the years, medical insurance expenditures have continued to increase, and it is an indisputable fact that medical insurance funds cannot make ends meet.
The inclusion of "Ixaprofen" in medical insurance will inevitably lead to a huge expenditure, which will undoubtedly make things worse.
"Okay, okay, definitely."
Everyone replied with a smile. This interruption made the originally solemn atmosphere relax a lot, and the seminar gradually got to the point.
This kind of seminar usually takes turns to speak. After a while, the microphone fell in front of an older man.
Zhou Hai looked over and saw the nameplate in front of the old man's conference table that read: Yao Haibo.
"Academician Yao, you are an expert in the field of biomedicine from the Chinese Academy of Sciences, and you have many years of experience in the research and development and marketing of innovative drugs. Could you please share your opinion?"
"Okay .”
Yao Haibo has nothing to do with it. He put on some airs, gently pushed the glasses on the bridge of his nose, and said in a deep voice:
“Dear leaders and colleagues, after receiving the notice of the seminar yesterday afternoon, I collected some information and made a set of plans. , now I will tell you what I think.”
"First of all, since Tsingshan Pharmaceutical has independently developed such an excellent innovative drug, we must first follow the market rules of innovative drugs and protect Tsingshan Pharmaceutical's economic interests in this."
“After all, everyone knows that the research and development of innovative drugs requires high investment and high risks. It is understandable to recover the costs and earn profits after success. "But, as Director Liu Weiguo said just now, we must consider the affordability of the Medical Insurance Bureau, so..."
"I think we can refer to the current situation of Gilead. How much does it cost for the company to cure a hepatitis C patient in China?”
How much does it cost to cure a hepatitis C patient?
Everyone nodded slightly. In 2019, "Sofosbuvir and Velpatasvir Tablets" under the name of the American company Gilead, which is often referred to as "G3" by patients, officially entered the national medical insurance and began the era of comprehensive cure of hepatitis C.
It is indeed a good idea to use existing similar drugs as a reference.
Yao Haibo continued:
“Gilead’s ‘Gilead Third Generation’ only needs to be taken for three months, and the cost after reimbursement for the entire course of treatment is about 6,000 yuan.”
“ Considering that there are only 10 million hepatitis C patients in China, and a full 120 million hepatitis B patients, the unit price must be lower than that of 'Ji San Dai'."
"I did a rough calculation, and I think it is more appropriate to control the cost of curing a hepatitis B patient at around 2,500 yuan."
"2,500 yuan?"
After the words fell, Liu Weiguo from the Medical Insurance Bureau took the lead. Wave your hands.
"Academician Yao, this price is too expensive, 2,500 yuan per person. Based on 120 million patients, that is a sales amount of 300 billion. Where does our medical insurance come from so much money?"
< br>Yao Haibo did not feel unhappy because of being interrupted, and replied seriously:
"120 million patients is a statistical standard. In fact, a large number of patients will not be cured, at least not at the first time."
"So, I think it is more appropriate to calculate based on a base of 30 million. 30 million times 2,500 yuan, Qingshan Pharmaceutical can have a sales amount of 75 billion, deducting R&D expenses and other He spent at least 10 billion yuan in profit. "
"The national medical insurance can reimburse 60% of the cost of 2,500 yuan, and the patient pays 40% out of his own pocket. After all, hepatitis B can be cured at 1,000 yuan. This price is very affordable for the patient. It’s absolutely acceptable.”
After the words fell, everyone present agreed.
It is already very impressive to earn more than 10 billion profits from a drug, and the medical insurance side bears 40% for patients and 60% for medical insurance, which is considered an acceptable threshold.
Only Liu Weiguo kept shaking his head.
“Too expensive, too expensive...”
With Academician Yao’s speech setting the tone, the following discussion will mainly focus on the reference point of Gilead’s “Gilead Third Generation” More in-depth discussion.
Perhaps because of Liu Weiguo’s strong opposition, after half an hour of discussion, everyone finally adopted the standard of 2,000 yuan to cure a hepatitis B patient as the psychological floor price for medical insurance negotiations.
In other words, Tsingshan Pharmaceutical's "Akofuvir" takes two months as a treatment course, and as long as the price per bottle is no more than 1,000 yuan, the Medical Insurance Bureau can accept it for inclusion in medical insurance.
Seeing that this seminar was about to be successfully completed, the host Zhou Hai couldn’t help but smile:
“Everyone, leaders, everyone has worked hard, but please remember the confidentiality clause and cannot reveal anything before it is implemented. News."
"Well, I know, I still have this awareness."
The atmosphere in the conference room became lively, and only Liu Weiguo, deputy director of the Medical Insurance Bureau, looked sad.
“Hey, let’s discuss whether the psychological price of 2,000 yuan can be lowered further? Where did our medical insurance fund come from so much money?!”
"Haha, Director Liu, this price is not expensive. After all, it is an innovative drug, and the patients also bear part of it."
"Yes, besides, this is a one-time cure. After the initial period, If you spend a large amount, the subsequent expenses will be much smaller. "
"Yes, you made it simple, but...there is another question, will Qingshan Pharmaceutical agree to this price?"
......
PS: Thank you Mo Huantian for the 5,000 coin reward! Updates will be added after they are released, remember!
Thank you all for your monthly votes, I feel your enthusiasm! Thanks!
(End of this chapter)